Evaluating the Role of ChatGPT in Educating Patients With Early-stage Hepatocellular Carcinoma

Launched by TAIPEI VETERANS GENERAL HOSPITAL, TAIWAN · Apr 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a chatbot powered by artificial intelligence, called ChatGPT, can help patients with early-stage liver cancer, also known as hepatocellular carcinoma. The goal is to see if this chatbot can provide clear and helpful information to patients and their families about their condition, treatment options, and what to expect, making it easier for them to understand and communicate with their healthcare providers.

To participate in the trial, you must be between 65 and 74 years old and have early-stage liver cancer (stages 0 to A). The researchers will divide participants into two groups: one will receive the usual educational materials about their condition, while the other will use the chatbot alongside the standard information. By comparing these two groups, the trial aims to find out if the AI tool improves patients' understanding and satisfaction with their care. If you're interested in learning more or think you might be eligible, this could be a valuable opportunity to help improve patient education for liver cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with early-stage hepatocellular carcinoma from both gastroenterology and general surgery outpatient departments were included. Early-stage hepatocellular carcinoma is defined based on the Barcelona Clinic Liver Cancer (BCLC) staging as stages 0 to A.
• Exclusion Criteria:
• • Patients under the age of 18 or those currently undergoing treatment for other cancers.